28 April 2023 in Frontiers in Veterinary Science
A 4-year-old neutered-male Australian Shepherd was presented to an emergency and referral hospital for an acute onset of neurologic signs and abnormal mentation. Seven days prior, the patient had been diagnosed with hypoadrenocorticism and was treated accordingly at another hospital. Based on recent clinical history, the neurologic signs were consistent with thalamic and brainstem deficits and suspected to be caused by osmotic demyelination syndrome secondary to rapid correction of hyponatremia. A brain MRI confirmed lesions consistent with osmotic demyelination syndrome. The patient's clinical signs initially worsened, and he required intensive nursing care with multimodal sedation, close monitoring of electrolytes and tailored fluid therapy. The patient recovered and was discharged on day seven of hospitalization. Four and a half months later, re-evaluation of the patient showed complete resolution of the neurological deficits with a now unremarkable neurological exam, and follow-up MRI revealed still present, yet improved bilateral thalamic lesions. This is the first known veterinary case report of sequential brain imaging of a dog that has recovered from osmotic demyelination syndrome. In humans, patients can have evidence of near to full clinical recovery, yet imaging findings may still be abnormal several months after recovery. This report details similar imaging findings in a canine with improved clinical signs, despite persistent lesions on brain MRI. Prognosis of canines with osmotic demyelination syndrome may be better than previously perceived, despite the severity of clinical signs and brain lesions apparent on MRI.
5 January 2024 in Frontiers in Veterinary Science
Introduction: Phenobarbital has been used for many decades in both human and veterinary epileptic patients. Many formulations for a particular drug exist, most of which are marketed for humans. Recently a veterinary specific phenobarbital product has been introduced to the market in the United States. Utilizing a specific formulation to treat patients may help decrease the issue of bioequivalence between one pharmaceutical product to another. Therefore, the goal of this study was to determine single and multiple dosing pharmacokinetics and tolerability of a veterinary specific phenobarbital product over a 4-week time period.Materials and methods: 8 Healthy dogs from a canine research colony were used in the study.Results: Overall, this phenobarbital formulation was well tolerated in the dogs in this study. Cmax, Tmax, half-life, and AUC after single 12 mg/kg oral dose were 23.5 μg/mL, 4.2 h, 94 h, and 2,758 h*μg/mL. Following chronic dosing, these parameters were 29.1 μg/mL, 3.4 h, 70 h, and 2,971 h*μg/mL, respectively.Discussion: This formulation demonstrated a mean absolute bioavailability of 100%, with similar pharmacokinetic properties to previously published data.
1 July 2024 in Journal of Veterinary Internal Medicine
Background: Syndecan-1 (SDC1) is an established marker of endothelial glycocalyx shedding. Most research on SDC1 has focused on plasma or serum concentrations, and little is known about urine concentrations. Objectives: Measure urinary SDC1 concentrations in dogs undergoing anesthesia with either sevoflurane or isoflurane and assess the effects of anesthesia duration and IV crystalloids on urinary SDC1 concentrations. Animals: Thirty-one client-owned dogs undergoing anesthesia for magnetic resonance imaging (MRI) with or without surgery for suspected intervertebral disk disease (IVDD) were used. Methods: Dogs with suspected IVDD were randomized to undergo anesthesia with either sevoflurane or isoflurane. Urine was collected before and immediately after anesthesia for the analysis of SDC1. Urinary creatinine concentrations also were measured, and the ratio of urinary SDC1 to urinary creatinine (USCR) was used to account for dilution. Results: Median (range) USCR was significantly higher after anesthesia compared with baseline for all groups combined (P < .05). No significant difference was found between the groups for age, sex, weight, and type of anesthesia. Multiple regression analysis of the effect of the independent variables inhalant type, age, weight, sex, anesthesia time, surgery, and quantity of IV fluids on the dependent variable SDC1 found that only the quantity of IV fluids significantly predicted a change (P < .001). Conclusions and Clinical Importance: The total volume of lactated Ringer's solution administered to anesthetized dogs may affect USCR. Further investigations are warranted to evaluate the relationship between IV fluids and SDC1.
17 July 2024 in Journal of Veterinary Pharmacology and Therapeutics
1 May 2025 in American Journal of Veterinary Research
Objective: To determine the effect of premedication followed by isoflurane (ISO) versus sevoflurane (SEVO), length of general anesthesia (GA), and the amount of IV fluid administered on plasma endocannabinoid arachidonoyl ethanolamide (anandamide; AEA) concentrations in dogs undergoing GA. Methods: This study was an analysis of samples collected during a previously designed prospective, randomized, single-blinded experimental study involving 21 client-owned dogs undergoing GA. Samples were collected from March through October 2021. Dogs were randomized to ISO or SEVO as the inhalant anesthetic. Blood samples collected before and after GA were used to measure plasma AEA concentrations using HPLC-MS-MS. Data included signalment, length of GA (minutes), surgery performed, fluid volume administered (milliliters per kilogram), and treatment with NSAIDs or steroids. Statistical analyses included power analysis, normality testing, and adjusted linear mixed models. Results: Plasma AEA concentrations significantly decreased after GA in both groups. Least squares mean AEA concentration decreased from 29 to 12.3 ng/mL in the ISO group and from 26.6 to 11.1 ng/mL in the SEVO group. There were no significant differences between groups or associations with anesthesia duration, fluid volume, surgery, or NSAID/steroid use. Conclusions: Plasma AEA concentrations were significantly reduced after GA in both the ISO and SEVO groups. This reduction may be influenced by other anesthesia agents, such as dexmedetomidine, hydromorphone, and propofol. Clinical Relevance: This study is the first to highlight a potential interaction between premedication, GA, and endocannabinoid signaling. Further research is needed to explore these findings and their implications for pain management and neuroprotection.